A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Pertuzumab|DRUG: Placebo|DRUG: Trastuzumab|DRUG: Docetaxel
Sponsor: Genentech, Inc.
Collaborators: Hoffmann-La Roche